Research progress in therapy drug monitoring of levetiracetam
Levetiracetam(LEV)is the second generation of broad-spectrum anti-epileptic drug.LEV has the advantages of rapid absorption,short half-life,precise efficacy,good tolerance and few drug interactions.In order to improve the clinical efficacy of LEV,and reduce the occurrence of adverse reactions,children,pregnant women,the elderly,and patients with renal insufficiency should receive therapeutic drug monitoring(TDM).Clinically,the samples are usually plasma or serum,and the TDM methods are mostly immunoassay or chromatography.There is currently no consensus on the effective concentration range of LEV,and the correlation between plasma concentration and adverse reactions is also unclear.The main factors affecting LEV plasma concentration include age,pregnancy,and patient compliance.How to interpret TDM results and adjust dosage based on the results will be the focus of future work.
levetiracetamtherapeutic drug monitoringrational drug useplasma concentration
国家科技期刊平台
NSTL
万方数据
维普
